-
1.发明公开
公开(公告)号：EP1141334A2
公开(公告)日：2001-10-10
申请号：EP99963641.8
申请日：1999-12-23
IPC分类号： C12N15/55
摘要： Glycosyl phosphatidy linositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.
-
2.发明公开GLYCOSYLPHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE D PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF ATHERSCLEROSIS 有权糖基化特异性磷脂酶D蛋白质用于治疗和动脉粥样硬化诊断
公开(公告)号：EP1294393A2
公开(公告)日：2003-03-26
申请号：EP01940840.0
申请日：2001-06-25
CPC分类号： C12Q1/44 , A61K38/00 , C12N9/16 , C12Y301/0405 , G01N33/564 , G01N33/573 , G01N2333/916
摘要： The present invention relates to the use of GPI-PLD for the prevention and treatment of conditions characterised by atherosclerosis. In some embodiments, this process may be caused by a failure to produce GPI-PLD, for example type 1 diabetes, or deliver GPI-PLD, such as patients deficient in apolipoprotein-A1, or those patients with autoantibodies to either GPI-PLD or Apo-A1. In other embodiments, the atherosclerotic process may result from a loss in GPI-PLD activity, e.g. where there is a genetic modification of GPI-PLD either affecting its activity or delivery to a target tissue, thereby leading to the atherosclerotic process.
-
3.发明公开MATERIALS AND METHODS RELATING TO THE TREATMENT OF CONDITIONS INVOLVING MAST CELLS, BASOPHILS AND EOSINOPHILS 有权IPG拮抗剂疾病的治疗中BASOPHILE-或嗜酸性粒细胞或肥大细胞发挥作用
公开(公告)号：EP1066043A2
公开(公告)日：2001-01-10
申请号：EP99913481.0
申请日：1999-03-29
IPC分类号： A61K31/70 , A61K39/395
摘要： This application discloses that inositolphosphoglycans (IPGs) can be obtained from basophils, eosinophils and mast cells and that allergen stimulation of these cells results in IPG release. It also shows that IPGs are second messengers for allergic stimulation as the addition of some types of purified IPGs to non-allergen stimulated cells resulted in histamine release or degranulation. Thus, IPG antagonists can be used for the treatment of conditions (especially allergy and asthma) mediated by the release of IPGs from mast cells, basophils or eosinophils. Preferred IPG antagonists include anti-IPG antibodies, inhibitors of the enzyme GPI-PLD and competitive antagonists.
-
4.发明授权GLYCOSYLPHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE D PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF ATHERSCLEROSIS 有权糖基化特异性磷脂酶D蛋白质用于治疗和动脉粥样硬化诊断
公开(公告)号：EP1294393B1
公开(公告)日：2005-10-05
申请号：EP01940840.0
申请日：2001-06-25
CPC分类号： C12Q1/44 , A61K38/00 , C12N9/16 , C12Y301/0405 , G01N33/564 , G01N33/573 , G01N2333/916
摘要： The present invention relates to the use of GPI-PLD for the prevention and treatment of conditions characterised by atherosclerosis. In some embodiments, this process may be caused by a failure to produce GPI-PLD, for example type 1 diabetes, or deliver GPI-PLD, such as patients deficient in apolipoprotein-A1, or those patients with autoantibodies to either GPI-PLD or Apo-A1. In other embodiments, the atherosclerotic process may result from a loss in GPI-PLD activity, e.g. where there is a genetic modification of GPI-PLD either affecting its activity or delivery to a target tissue, thereby leading to the atherosclerotic process.
-
5.发明授权MATERIALS FOR THE TREATMENT OF CONDITIONS INVOLVING MAST CELLS, BASOPHILS AND EOSINOPHILS 有权用于疾病的治疗材料，其中BASOPHILE-或嗜酸性粒细胞或肥大细胞发挥作用
公开(公告)号：EP1066043B1
公开(公告)日：2003-12-17
申请号：EP99913481.0
申请日：1999-03-29
IPC分类号： A61K31/7004 , A61K39/395 , A61P37/08
摘要： This application discloses that inositolphosphoglycans (IPGs) can be obtained from basophils, eosinophils and mast cells and that allergen stimulation of these cells results in IPG release. It also shows that IPGs are second messengers for allergic stimulation as the addition of some types of purified IPGs to non-allergen stimulated cells resulted in histamine release or degranulation. Thus, IPG antagonists can be used for the treatment of conditions (especially allergy and asthma) mediated by the release of IPGs from mast cells, basophils or eosinophils. Preferred IPG antagonists include anti-IPG antibodies, inhibitors of the enzyme GPI-PLD and competitive antagonists.
-
-
-
-
搜索结果
5 条记录 (耗时 0.009 秒)
